HALO - Halozyme Therapeutics +13% On Thursday: What's Going On? | Benzinga
Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares are trading higher on the bourses on Thursday after it raised its FY24 guidance.
The company sees full-year 2024 total revenue of $935 million to $1.015 billion versus $947.33 million estimate (prior view: $915 million to $985 million), representing growth of 13% to 22% over 2023.
The company projected revenue from royalties of $520 million to $555 million (prior view: $500 million-$525 million), representing growth of 16% to 24% over ...